Sung‐Bae Kim

Ulsan College — South Korea

Medicine · Health Sciences

74h-index41.5kcitations716works9.12yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

HER2/EGFR in Cancer Research(162), Cancer Treatment and Pharmacology(129), Advanced Breast Cancer Therapies(123), Breast Cancer Treatment Studies(121), Esophageal Cancer Research and Treatment(84)

Publications716 total

Imlunestrant with or without abemaciclib in advanced breast cancer: updated efficacy results from the phase III EMBER-3 trial
Annals of Oncology·2025· 1 citedOpen Access
Pembrolizumab plus chemotherapy versus chemotherapy for advanced esophageal cancer: 5-year extended follow-up for the randomized phase III KEYNOTE-590 study
ESMO Open·2025· 2 citedOpen Access
580 Phase 1 study of mitotic checkpoint inhibitor BAL0891 in combination with tislelizumab (anti-PD-1 antibody) in patients with advanced solid tumors
Regular and Young Investigator Award Abstracts·2025Open Access
Genomic and transcriptomic analyses of residual invasive triple-negative breast cancer after neoadjuvant chemotherapy in the prospective MIRINAE trial (a randomized phase II trial of adjuvant atezolizumab plus capecitabine compared to capecitabine; KCSG-BR18-21)
ESMO Open·2025Open Access
Reply to: Germline and Somatic <i>BRCA1/2</i> Mutations in Breast Cancer Treatment Strategies
JCO Precision Oncology·2025
ASO Visual Abstract: Analysis of Recurrence Sites in Esophageal Squamous Cell Carcinoma After Neoadjuvant Chemoradiation with Elective Nodal Irradiation: Insights for Radiation Field Optimization
Annals of Surgical Oncology·2025
Distinct Prognostic Roles of <sup>18</sup>F-FDG PET Metabolic Response Assessed After Induction Chemotherapy or Chemoradiotherapy in Localized Esophageal Squamous Cell Carcinoma
Journal of Nuclear Medicine·2025· 1 cited
Supplementary Data 1 from INTERLINK-1: A Phase III, Randomized, Placebo-Controlled Study of Monalizumab plus Cetuximab in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
2025Open Access
Data from INTERLINK-1: A Phase III, Randomized, Placebo-Controlled Study of Monalizumab plus Cetuximab in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
2025Open Access
Abstract PS17-10: Genomic and transcriptomic analyses of residual invasive triple-neg breast cancer after neoadjuvant chemotherapy in prospective MIRINAE trial (a randomized phase II trial of adjuvant atezolizumab + capecitabine versus capecitabine; KCSG-BR18-21)
Clinical Cancer Research·2025
Abstract P4-04-28: PF-07248144, a first-in-class KAT6 inhibitor, in patients with HR+ HER2− metastatic breast cancer: Updated results from phase 1 dose expansion study
Clinical Cancer Research·2025· 1 cited
LiGeR-HN phase III trials of petosemtamab + pembrolizumab and petosemtamab monotherapy in recurrent or metastatic HNSCC
Future Oncology·2025· 3 citedOpen Access
Abstract GS1-01: Imlunestrant, an Oral Selective Estrogen Receptor Degrader (SERD), as Monotherapy &amp; Combined with Abemaciclib, for Patients with ER+, HER2- Advanced Breast Cancer (ABC), Pretreated with Endocrine Therapy (ET): Results of the Phase 3 EMBER-3 trial
Clinical Cancer Research·2025· 1 cited
Abstract P1-09-06: Evaluation of proliferation biomarker serum thymidine kinase activity and prediction of early relapse in HR positive HER2 negative high risk early breast cancer: Analysis from the PENELOPE-B trial
Clinical Cancer Research·2025· 1 cited
Phase I and II Clinical Studies of the STING Agonist Ulevostinag with and without Pembrolizumab in Participants with Advanced or Metastatic Solid Tumors or Lymphomas
Clinical Cancer Research·2025· 19 cited
Sacituzumab govitecan (SG) + pembrolizumab (pembro) vs chemotherapy (chemo) + pembro in previously untreated PD-L1–positive advanced triple-negative breast cancer (TNBC): Primary results from the randomized phase 3 ASCENT-04/KEYNOTE-D19 study.
Journal of Clinical Oncology·2025· 34 cited
Patient-reported outcomes (PROs) in patients with ER+, HER2- advanced breast cancer (ABC) treated with imlunestrant, investigator’s choice standard endocrine therapy, or imlunestrant + abemaciclib: Results from the phase III EMBER-3 trial.
Journal of Clinical Oncology·2025· 4 cited
Dose optimization of PF-07248144, a first-in-class KAT6 inhibitor, in patients (pts) with ER+/HER2− metastatic breast cancer (mBC): Results from phase 1 study to support the recommended phase 3 dose (RP3D).
Journal of Clinical Oncology·2025· 2 cited
Phase III of oral paclitaxel (DHP107) vs intravenous paclitaxel in HER2-negative recurrent or metastatic breast cancer (mBC): Primary analysis of a multinational optimal trial (NCT03315364).
Journal of Clinical Oncology·2025· 1 cited
INTERLINK-1: A Phase III, Randomized, Placebo-Controlled Study of Monalizumab plus Cetuximab in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Clinical Cancer Research·2025· 8 citedOpen Access
page 1 of 36Next →

Frequent Co-authors

Seock‐Ah Im(13), Javier Cortés(10), Cristina Saura(7), Jean-­Marc Ferrero(6), Fabrice André(6), Ken Kato(6), Sandra M. Swain(5), Joohyuk Sohn(5), Jungsil Ro(5), Sara A. Hurvitz(5), Myung‐Ju Ahn(5), Miguel Martín(5), Giuseppe Curigliano(5), Michelino De Laurentiis(5), Roberto Hegg(4), Young‐Hyuck Im(4), Emma Clark(4), Mark Benyunes(4), Keun Seok Lee(4), Yeon Hee Park(4)